The Anti-Diabetes Drugs market in Belgium has been experiencing steady growth in recent years.
Customer preferences: Belgian consumers are increasingly concerned about their health and are actively seeking out ways to prevent and manage chronic diseases such as diabetes. As a result, there is a growing demand for anti-diabetes drugs in the country. Patients are also becoming more informed about the different treatment options available to them and are seeking out drugs that have fewer side effects and are more effective in managing their condition.
Trends in the market: One of the key trends in the Anti-Diabetes Drugs market in Belgium is the increasing use of combination therapies. Many patients are now using more than one drug to manage their condition, as this has been shown to be more effective in controlling blood sugar levels. There is also a growing trend towards the use of newer drugs such as GLP-1 agonists and SGLT2 inhibitors, which have been shown to be more effective in managing diabetes than older drugs such as metformin.
Local special circumstances: Belgium has a well-developed healthcare system, which provides patients with access to a wide range of treatments for diabetes. The country also has a high level of diabetes awareness, with many healthcare professionals actively promoting the importance of early diagnosis and effective management of the condition. This has helped to drive demand for anti-diabetes drugs in the country.
Underlying macroeconomic factors: One of the key macroeconomic factors driving the growth of the Anti-Diabetes Drugs market in Belgium is the ageing population. As the population ages, the prevalence of diabetes is expected to increase, which will drive demand for anti-diabetes drugs. Another factor is the increasing prevalence of obesity, which is a major risk factor for diabetes. As obesity rates continue to rise in Belgium, the demand for anti-diabetes drugs is likely to increase further. Finally, the increasing availability of health insurance in the country is also driving demand for anti-diabetes drugs, as more people are able to afford the cost of treatment.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
